Mission
To develop safe and effective new drugs for treatment of a broad spectrum of diseases for which there are currently limited treatment options, using our disruptive, high-throughput drug development technology and Artificial Intelligence/Machine Learning/Deep Learning (AL/ML/DL) which together are transformative in the drug development industry.
Values
Focusing on the best interests of the patients we serve, we
To develop safe and effective new drugs for treatment of a broad spectrum of diseases for which there are currently limited treatment options, using our disruptive, high-throughput drug development technology and Artificial Intelligence/Machine Learning/Deep Learning (AL/ML/DL) which together are transformative in the drug development industry.
Values
Focusing on the best interests of the patients we serve, we
Location: United States
Employees: 1-10
Total raised: $200M
Investors 2
| Date | Name | Website |
| 21.09.2021 | Breyer Cap... | breyercapi... |
| 10.08.2022 | Xandex Ven... | xandexvent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.01.2026 | Series C | $200M | Breyer Cap... |
Mentions in press and media 5
| Date | Title | Description |
| 11.01.2026 | Soley Therapeutics Secures $200M Series C, Propelling AI-Driven Oncology and Neurodegenerative Programs to Clinic | Soley Therapeutics locked in $200 million in Series C funding. This major capital injection drives two oncology programs into clinical development, focusing on acute myeloid leukemia (AML) and solid tumors. The funds also support non-oncolo... |
| 08.01.2026 | Soley Therapeutics: $200 Million Series C Closed To Advance Oncology Assets Into the Clinic | Soley Therapeutics has raised $200 million in Series C funding to move its cell stress-sensing platform and pipeline into clinical development, including IND-enabling work and trials for two first-in-class, internally discovered oncology pr... |
| 08.01.2026 | Soley Therapeutics Raises $200M in Series C Financing | Soley Therapeutics, a San Francisco, CA-based drug discovery and development company, raised $200M in Series C funding. The round was led by Surveyor Capital with participation from HRTG Partners, RWN Management, and others. Existing invest... |
| 07.01.2026 | Soley secures $200M series C to push AML cell stress drug into clinic | Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use to take its lead acute myeloid leukemia (AML) asset into the clinic. The South San Francisco-based company’s pipel... |
| - | Soley Therapeutics | “Soley Therapeutics’ high-throughput evaluation platform decodes Cellular Language and uses the power of AI/ML to discover and develop drugs.” |